Pulmonary Hypertension Clinical Trials

Find Pulmonary Hypertension Clinical Trials Near You

Evaluation of the BMPR2-Activin Signaling Pathway as a Key Mediator in Group II Pulmonary Hypertension. BREATHE-PH Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin. Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology. Its aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD. We will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment. Clinical parameters, biomarkers, molecular profiles, and hemodynamic/echocardiographic variables will be analyzed. A nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls. We will also assess reversibility of vascular remodeling one year after transplantation. Results may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Older that 18 years

• Heart failled patients with clinical indication for invasive hemodynamic assessment

• Written consent

Locations
Other Locations
Spain
Hospital GU Gregorio Marañón
RECRUITING
Madrid
Contact Information
Primary
Ana I Fernandez-Avila, PhD
afernandeza.externo@salud.madrid.org
+34650413943
Backup
Jorge Martinez-Solano, MD, PhD
jmsolano@salud.madrid.org
Time Frame
Start Date: 2025-11-01
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 150
Sponsors
Collaborators: Instituto de Investigación Sanitaria Gregorio Marañón, Fundacion para la Innovacion en Biomedicina (FIBMED)
Leads: Hospital General Universitario Gregorio Marañon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials